相关临床试验
206
23 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1978
进行中（未招募）
4
1.9%
已完成
131
63.6%
Enrolling By Invitation
4
1.9%
尚未招募
15
7.3%
招募中
13
6.3%
终止
1
0.5%
Unknown
38
18.4%
暂无批准数据
- Bangladesh's government announced it will formulate a national strategy to advance the pharmaceutical industry toward biosimilars, vaccines, and biotechnology, moving beyond its generic drug base. - Industry stakeholders called for an integrated Life Science and Biopharmaceutical Strategy by 2035, emphasizing technology transfer, clinical research, regulatory accreditation, and workforce development. - The transformation will require roughly 10,000 trained professionals, with proposals for shared infrastructure, a biosimilar center of excellence, and strengthened regulatory capacity aligned with international standards. - Experts highlighted gaps in cell-line development, sequencing, and bioinformatics, while noting icddr,b's capacity to conduct more than 100 vaccine trials could accelerate clinical research.
- Researchers at Washington University School of Medicine discovered that ETEC and Shigella rely on three closely related enzymes — EatA, SepA, and Pic — to penetrate the gut's protective mucus layer and cause infection. - Antibodies targeting a shared region of these enzymes were shown to neutralize all three, blocking the bacteria from breaching the intestinal mucus barrier, based on samples from infected patients and controlled human challenge studies. - Cryo-electron microscopy performed at the University of Missouri pinpointed the precise binding site of the most effective neutralizing antibodies, establishing a foundation for rational vaccine design. - The findings, published June 15 in PNAS, suggest a single combination vaccine could protect against multiple major causes of severe diarrhea, addressing a long-standing unmet need for children in endemic regions and travelers worldwide.
- The University of Oxford has initiated the world's first Phase II clinical trial of a Nipah virus vaccine candidate in Bangladesh, marking a critical milestone in pandemic preparedness efforts. - The ChAdOx1 NipahB vaccine trial will enroll 306 healthy participants aged 18-55 to assess safety and immune response in a region experiencing regular Nipah outbreaks. - Nipah virus poses a severe public health threat with a case fatality rate of up to 75% and is recognized by WHO as a priority pathogen with pandemic potential. - The vaccine uses the same viral vector platform as the Oxford/AstraZeneca COVID-19 vaccine and has received PRIME designation from the European Medicines Agency to expedite development.
- The WHO has approved Cecolin, a bivalent HPV vaccine, for single-dose use, potentially revolutionizing cervical cancer prevention efforts globally. - A clinical trial (CVIA 087) conducted by icddr,b and partners demonstrated the safety and efficacy of single-dose Cecolin vaccination. - The approval aims to address vaccine supply challenges and improve access in low- and middle-income countries, where 90% of cervical cancer deaths occur. - Health officials urge vaccination for girls aged 10-14, highlighting it as a critical opportunity to protect against HPV-related cervical cancer.
